Literature DB >> 12232795

T cell apoptosis by tryptophan catabolism.

F Fallarino1, U Grohmann, C Vacca, R Bianchi, C Orabona, A Spreca, M C Fioretti, P Puccetti.   

Abstract

Indoleamine 2,3-dioxygenase (IDO) is a tryptophan-catabolizing enzyme that, expressed by different cell types, has regulatory effects on T cells resulting from tryptophan depletion in specific local tissue microenvironments. Different mechanisms, however, might contribute to IDO-dependent immune regulation. We show here that tryptophan metabolites in the kynurenine pathway, such as 3-hydroxyanthranilic and quinolinic acids, will induce the selective apoptosis in vitro of murine thymocytes and of Th1 but not Th2 cells. T cell apoptosis was observed at relatively low concentrations of kynurenines, did not require Fas/Fas ligand interactions, and was associated with the activation of caspase-8 and the release of cytochrome c from mitochondria. When administered in vivo, the two kynurenines caused depletion of specific thymocyte subsets in a fashion qualitatively similar to dexamethasone. These data suggest that the selective deletion of T lymphocytes may be a major mechanism whereby tryptophan metabolism affects immunity under physiopathologic conditions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12232795     DOI: 10.1038/sj.cdd.4401073

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  314 in total

Review 1.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

Review 2.  Eosinophils in innate immunity: an evolving story.

Authors:  Revital Shamri; Jason J Xenakis; Lisa A Spencer
Journal:  Cell Tissue Res       Date:  2010-11-03       Impact factor: 5.249

3.  An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells.

Authors:  Joshua D Mezrich; John H Fechner; Xiaoji Zhang; Brian P Johnson; William J Burlingham; Christopher A Bradfield
Journal:  J Immunol       Date:  2010-08-18       Impact factor: 5.422

Review 4.  Dendritic cells: The warriors upfront-turned defunct in chronic hepatitis C infection.

Authors:  Meenakshi Sachdeva; Yogesh K Chawla; Sunil K Arora
Journal:  World J Hepatol       Date:  2015-09-08

5.  LW106, a novel indoleamine 2,3-dioxygenase 1 inhibitor, suppresses tumour progression by limiting stroma-immune crosstalk and cancer stem cell enrichment in tumour micro-environment.

Authors:  Rong Fu; Yi-Wei Zhang; Hong-Mei Li; Wen-Cong Lv; Li Zhao; Qing-Long Guo; Tao Lu; Stephen J Weiss; Zhi-Yu Li; Zhao-Qiu Wu
Journal:  Br J Pharmacol       Date:  2018-06-03       Impact factor: 8.739

Review 6.  IDO-expressing regulatory dendritic cells in cancer and chronic infection.

Authors:  Alexey Popov; Joachim L Schultze
Journal:  J Mol Med (Berl)       Date:  2007-09-18       Impact factor: 4.599

7.  Cell-type deconvolution with immune pathways identifies gene networks of host defense and immunopathology in leprosy.

Authors:  Megan S Inkeles; Rosane Mb Teles; Delila Pouldar; Priscila R Andrade; Cressida A Madigan; David Lopez; Mike Ambrose; Mahdad Noursadeghi; Euzenir N Sarno; Thomas H Rea; Maria T Ochoa; M Luisa Iruela-Arispe; William R Swindell; Tom Hm Ottenhoff; Annemieke Geluk; Barry R Bloom; Matteo Pellegrini; Robert L Modlin
Journal:  JCI Insight       Date:  2016-09-22

Review 8.  The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways.

Authors:  Riekelt H Houtkooper; Carles Cantó; Ronald J Wanders; Johan Auwerx
Journal:  Endocr Rev       Date:  2009-12-09       Impact factor: 19.871

Review 9.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 10.  Harnessing the immune system to treat cancer.

Authors:  Nina Bhardwaj
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.